Wall Street analysts expect Mylan (NASDAQ:MYL) to announce $3.27 billion in sales for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Mylan’s earnings, with estimates ranging from $3.19 billion to $3.34 billion. Mylan also reported sales of $3.27 billion during the same quarter last year. The firm is scheduled to announce its next quarterly earnings results after the market closes on Wednesday, February 28th.
On average, analysts expect that Mylan will report full-year sales of $3.27 billion for the current fiscal year, with estimates ranging from $11.86 billion to $12.03 billion. For the next financial year, analysts forecast that the business will report sales of $12.64 billion per share, with estimates ranging from $12.30 billion to $13.10 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that that provide coverage for Mylan.
A number of research firms have recently commented on MYL. JPMorgan Chase & Co. set a $53.00 price objective on Mylan and gave the stock a “buy” rating in a report on Friday, February 16th. TheStreet downgraded Mylan from a “b-” rating to a “c+” rating in a report on Friday, February 9th. BidaskClub downgraded Mylan from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Susquehanna Bancshares reiterated a “positive” rating and issued a $55.00 price target (up from $47.00) on shares of Mylan in a report on Thursday, January 25th. Finally, Deutsche Bank set a $50.00 price target on Mylan and gave the company a “buy” rating in a report on Wednesday, January 24th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $44.89.
In other news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is owned by company insiders.
Several institutional investors have recently made changes to their positions in MYL. Meeder Asset Management Inc. grew its stake in shares of Mylan by 76.9% during the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after acquiring an additional 1,475 shares in the last quarter. State Treasurer State of Michigan lifted its position in shares of Mylan by 7.4% during the third quarter. State Treasurer State of Michigan now owns 162,709 shares of the company’s stock worth $5,104,000 after purchasing an additional 11,200 shares during the last quarter. Gilman Hill Asset Management LLC lifted its position in shares of Mylan by 9.9% during the third quarter. Gilman Hill Asset Management LLC now owns 14,527 shares of the company’s stock worth $456,000 after purchasing an additional 1,310 shares during the last quarter. Whittier Trust Co. lifted its position in shares of Mylan by 3.4% during the third quarter. Whittier Trust Co. now owns 77,479 shares of the company’s stock worth $2,429,000 after purchasing an additional 2,554 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its position in shares of Mylan by 4.8% during the third quarter. Nationwide Fund Advisors now owns 461,279 shares of the company’s stock worth $14,470,000 after purchasing an additional 21,184 shares during the last quarter. Institutional investors own 76.86% of the company’s stock.
Shares of Mylan (NASDAQ MYL) opened at $41.28 on Friday. The company has a market capitalization of $22,106.54, a price-to-earnings ratio of 8.77, a PEG ratio of 1.11 and a beta of 1.35. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan has a twelve month low of $29.39 and a twelve month high of $47.82.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.